Home  »  Business   »  We Analyzed the Future Direction of Cardiff Oncolo...

We Analyzed the Future Direction of Cardiff Oncology Inc. (CRDF), Here is What We Found

Cardiff Oncology Inc. (NASDAQ:CRDF) went up by 6.98% from its latest closing price compared to the recent 1-year high of $7.32. The company’s stock price has collected 6.15% of gains in the last five trading sessions.

Is It Worth Investing in Cardiff Oncology Inc. (NASDAQ :CRDF) Right Now?

Plus, the 36-month beta value for CRDF is at 1.53. Opinions of the stock are interesting as 4 analysts out of 5 who provided ratings for Cardiff Oncology Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

The average price from analysts is $8.00, which is $6.62 above the current price. CRDF currently public float of 41.40M and currently shorts hold a 3.14% ratio of that float. Today, the average trading volume of CRDF was 545.63K shares.

CRDF’s Market Performance

CRDF stocks went up by 6.15% for the week, with a monthly drop of -9.21% and a quarterly performance of -50.71%, while its annual performance rate touched -74.35%. The volatility ratio for the week stands at 8.74% while the volatility levels for the past 30 days are set at 6.99% for Cardiff Oncology Inc. The simple moving average for the period of the last 20 days is -1.36% for CRDF stocks with a simple moving average of -32.73% for the last 200 days.

Analysts’ Opinion of CRDF

Robert W. Baird, on the other hand, stated in their research note that they expect to see CRDF reach a price target of $19. The rating they have provided for CRDF stocks is “Outperform” according to the report published on December 08th, 2021.

Maxim Group gave a rating of “Buy” to CRDF, setting the target price at $20 in the report published on August 09th of the previous year.

CRDF Trading at -8.32% from the 50-Day Moving Average

After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.15% of loss for the given period.

Volatility was left at 6.99%, however, over the last 30 days, the volatility rate increased by 8.74%, as shares sank -10.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.81% lower at present.

During the last 5 trading sessions, CRDF rose by +6.15%, which changed the moving average for the period of 200-days by -58.68% in comparison to the 20-day moving average, which settled at $1.3905. In addition, Cardiff Oncology Inc. saw -77.04% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CRDF starting from White Lale, who purchase 15,000 shares at the price of $1.64 back on Sep 19. After this action, White Lale now owns 113,788 shares of Cardiff Oncology Inc., valued at $24,525 using the latest closing price.

Armitage James O, the Director of Cardiff Oncology Inc., purchase 13,000 shares at $1.56 during a trade that took place back on Sep 16, which means that Armitage James O is holding 13,000 shares at $20,233 based on the most recent closing price.

Stock Fundamentals for CRDF

Current profitability levels for the company are sitting at:

  • -8037.60 for the present operating margin
  • -39.28 for the gross margin

The net margin for Cardiff Oncology Inc. stands at -7880.50. Equity return is now at value -31.30, with -29.00 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 22.28.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]